Groups receive nearly $2M in funding for cancer research

Oncopole, a Montreal-based research center, announced that five teams won the Onco-Tech Competition and will receive a total of $1.97 ($2.6 million CAD) in funding. The five winning projects all aim to use advanced technologies, including AI, to improve care for cancer patients.

The Onco-Tech Competition is a joint collaboration between Oncopole, the MEDTEQ Consortium, the TransMedTech Institute and the Cancer Research Society. The contest “is an opportunity for Quebec investigators to accelerate the development, validation and marketing of new medical technologies in oncology, for the benefit of patients,” according to a prepared statement.

The five winning projects are:

  • “Better classification of mammographic abnormalities using artificial intelligence”
  • “Towards a better quantitative and multiplexed lung cancer diagnosis using metallic nanoparticles”
  • “Predicting the clinical response to immunotherapy for lung cancer patients, using artificial intelligence”
  • “Better detection of hepatocellular carcinomas to improve the effectiveness of liver cancer treatments using novel algorithms”
  • “A predictive platform of radiation treatments using breakthroughs in artificial intelligence”

“This major funding will enable the projects selected to benefit from targeted and complementary expertise to accelerate the development of new medical technologies, providing hope in the fight against cancer,” according to the statement.   

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.